Respiratory disease

Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing

Retrieved on: 
Tuesday, January 30, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Urinary tract infection, Chronic obstructive pulmonary disease, CFTR, Mortality, FEV1, Respiratory disease, Therapy, Disease, Patient, Enterprise, Mucus, IP Group, Cystic fibrosis, Epithelial sodium channel, Asthma, Atomic mass

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

Key Points: 
  • Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.
  • Existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group also participated.
  • Alongside the financing, Dr Rob Woodman, Partner at Panakes, joins Enterprise’s Board of Directors.
  • Dr John Ford, CEO, Enterprise Therapeutics, said: “We have made tremendous progress to date in developing novel therapeutics for patients suffering from chronic respiratory diseases.

VMX 2024 Showcased Groundbreaking Innovations in Veterinary Medicine to Provide the Best Care for Pets Around the World

Retrieved on: 
Thursday, January 18, 2024
Hill, Research, MRI, Animal, VMX, Pain management, Otter, Magic, Expo Hall, Horse, DVM, World's fair, Diagnosis, Veterinarian, Roger Hawkins (drummer), Osteoarthritis, Diabetes, Pet, DEI, Radiology, Bacteria, OA, Disease, Education, Artificial intelligence, Veterinary medicine, CAE, AI, Quality of life, Fantasy, Cat, Dog, CE, Patient, Internal medicine, Texas A&M University, The Show of Shows, Respiratory disease, Nap, FDA, Pet industry

ORLANDO, Fla. , Jan. 18, 2024 /PRNewswire/ -- The North American Veterinary Community (NAVC) concluded its 41st annual Veterinary Meeting and Expo (VMX 2024) Jan. 17, kicking off the new year with the latest product introductions and innovations and setting the direction for the $104 billion animal health care industry in 2024. More than 27,000 people attended the event from 82 countries with 8,700 first-time attendees. Nearly 26,000 were in person, representing a local economic impact exceeding $65.3 million.

Key Points: 
  • "VMX 2024 was truly the Show of Shows and brought the best in education and new technologies and products that are transforming veterinary medicine, plus invaluable networking opportunities and headlining entertainment.
  • "At the end of the day, what we're trying to do is provide the best care for pets around the world.
  • "At VMX 2024, we saw things that once sounded like fantasy now become a reality," said NAVC Chief Veterinary Officer Dana Varble, DVM, CAE.
  • Technology to assess animal pain and help pet owners and veterinary professionals provide the best care to all companion animals.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Mobile Grooming Offers Safe Solution for Dogs Amidst Mysterious Respiratory Illness Outbreak

Retrieved on: 
Wednesday, January 10, 2024
Infection, Animal, Health, Cough, Sneeze, Dog, Respiratory disease, Pet, Risk, Safety, Veterinary medicine

Furry Land Mobile Grooming is tailored to meet the unique needs of pet owners.

Key Points: 
  • Furry Land Mobile Grooming is tailored to meet the unique needs of pet owners.
  • Mobile grooming , a growing trend in the pet industry, offers a safe and convenient solution for keeping dogs healthy.
  • As the spread of this mysterious respiratory illness continues to be a concern nationwide, Furry Land Mobile Grooming offers a safe and convenient solution for keeping dogs healthy.
  • With their mobile grooming services, pet owners can rest assured that their furry companions can receive the grooming care they need without any added risk.

The Lung Center at Mercy Introduces Interventional Pulmonology

Retrieved on: 
Wednesday, January 3, 2024
Magnet, Weinberg Center, Neuromuscular disease, Body cavity, Multimedia, Division, Sister, Elective surgery, Respiratory disease, Sleep, COPD, The Sisters of Mercy, Lung cancer, Disease, Interventional pulmonology, Pulmonology, Pleural cavity, Cancer, Sarcoidosis, Health, Asthma, Glen Burnie, Maryland, IP, Patient, Mercy Hospital, Diagnosis, Radiation, Nursing

BALTIMORE, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Lung Center at Mercy Medical Center is expanding to include Interventional Pulmonology (IP), Albert J. Polito, M.D., Medical Director of The Lung Center and Chief of the Division of Pulmonary Medicine at Mercy, has announced. The expansion will essentially double the size of Mercy's current Lung Center with greater access for pulmonary patients.

Key Points: 
  • Interventional Pulmonology (IP) at Mercy Provides Minimally Invasive Procedures to Diagnose & Treat Lung Disease, Cancer / Mercy First in Maryland to Offer New Integrated Robotic Lung Navigational Technology
    BALTIMORE, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Lung Center at Mercy Medical Center is expanding to include Interventional Pulmonology (IP) , Albert J. Polito, M.D.
  • , Medical Director of The Lung Center and Chief of the Division of Pulmonary Medicine at Mercy, has announced.
  • Beyond the downtown location, Mercy Lung Center staff see patients at the Overlea, Lutherville, Reisterstown, and Glen Burnie sites of Mercy Personal Physicians.
  • Founded in 1874 by The Sisters of Mercy, Mercy is home to the acclaimed Weinberg Center for Women's Health & Medicine and the $400+ million, 20-story Mary Catherine Bunting Center.

MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

Retrieved on: 
Wednesday, December 13, 2023
Hydrogen, Giovinazzo, Conference, Neuromuscular disease, Biotechnology, Muscular dystrophy, Research, COPD, Episcopal conference, University, Therapy, Degenerative disease, Mitochondrion, Respiratory disease, Abstract, Neuroprotection, DMD, Hydrogen sulfide, Duchenne, Inflammation, Patient, Dementia, Investment, Pharmaceutical industry

OXFORD, United Kingdom, Dec. 13, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the final close of its seed extension financing round, with £4m raised to date from existing investors.

Key Points: 
  • OXFORD, United Kingdom, Dec. 13, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the final close of its seed extension financing round, with £4m raised to date from existing investors.
  • The platform is extendable to other degenerative diseases, and additional evidence has been generated in a mammalian respiratory disease model through its academic collaborators.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “Degenerative diseases place great burdens on patients and healthcare systems.
  • This seed extension financing round enables us to advance a lead asset toward the clinic and provides a firm foundation to secure a Series A to take us to the clinic within two years.

Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections

Retrieved on: 
Tuesday, November 28, 2023
RNA, Health care, Biotechnology, Messenger, Medication, Vaccine, MHRA, Asthma, Respiratory disease, Patient, Therapy, CTA, Pharmaceutical industry

MUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH , a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.

Key Points: 
  • MUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH , a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.
  • The authorization follows Ethris’ submission of a Clinical Trial Authorization (CTA) application to the MHRA in June 2023.
  • The Phase 1 study is expected to commence in the U.K in December 2023.
  • “Receiving regulatory clearance from U.K.’s MHRA for our inhaled mRNA-based drug candidate ETH47 and its imminent entry into the clinic marks a significant milestone for Ethris” said Dr. Carsten Rudolph, CEO of Ethris.

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Retrieved on: 
Thursday, December 21, 2023
Long COVID, Long, Urinary tract infection, Immunology, University of Manchester, Immune system, Research, Trial of the century, University, Viral, Respiratory disease, Observational study, Immunity, Inflammation, IVD, Patient, Diagnosis, Vaccine

This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.

Key Points: 
  • This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.
  • Furthermore, within the ImRESP clinical study, the T-cell assay will be assessed in a distinct cohort of patients experiencing Long COVID symptoms.
  • This collaboration underscores Virax Biolabs' commitment to advancing diagnostic capabilities and understanding immune responses, particularly in post-viral syndromes and conditions associated with chronic inflammation.
  • The collaboration with the University of Manchester represents a significant step toward developing innovative solutions for diagnosing and managing post-viral syndromes.

Experts on AI, the "Mystery Dog Illness" and the State of Pet Care in Ukraine to Speak at VMX 2024

Retrieved on: 
Wednesday, December 20, 2023
Student, Research, Informatics, CE, Doctor of Philosophy, College, ChatGPT, Agriculture, Health, VMX, AI, University, DVM, Respiratory disease, Dog, Animal, Infection, Expo Hall, MARS, Veterinarian, Horizon, Orange County Convention Center, Veterinary medicine

ORLANDO, Fla., Dec. 20, 2023 /PRNewswire/ -- Jan. 13 -17, 2024, the North American Veterinary Community (NAVC) will host VMX 2024 in Orlando, FL, setting the direction for veterinary medicine in the new year and providing industry professionals with more than 800 continuing education and scientific sessions presented by world-renowned veterinary leaders. VMX features subject matter experts on the top current events in veterinary medicine to help veterinary professionals expand their skills and be on the cutting edge of what's new and notable.

Key Points: 
  • VMX features subject matter experts on the top current events in veterinary medicine to help veterinary professionals expand their skills and be on the cutting edge of what's new and notable.
  • VMX 2024 will feature world-renowned animal healthcare experts who are available for interviews.
  • His session takes place at 4:15 p.m. in the VMX Sound Stage, Booth 315, in the Expo Hall.
  • His session takes place at 1-2 p.m. January 14 in the VMX Sound Stage Booth 315 in the Expo Hall.

Genetic Testing's Role in Personalized Medicine and Targeted Therapies for Respiratory Conditions - ResearchAndMarkets.com

Retrieved on: 
Monday, December 18, 2023
Health, Genetics, Personalized medicine, COPD, Genome-wide association study, Disorder, Prevalence, Granulomatous–lymphocytic interstitial lung disease, Privacy, Risk, Diagnosis, GWAS, Respiratory disease, Marker beacon, Region, Genetic testing, Health information management, Growth, Chronic obstructive pulmonary disease, Asthma, Cystic fibrosis, Agriculture, Pharmaceutical industry, Vaccine, Medical device

Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.

Key Points: 
  • Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.
  • Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.
  • Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.
  • Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.